جستجوی استاد راهنمای دانشگاهی

Carol R Kuntz serves as an Adjunct Professor in the Science, Technology and International Affairs (STIA) program at Georgetown University, teaching courses on artificial intelligence policy implications. She concurrently holds an adjunct fellowship at the Center for Strategic and International Studies (CSIS) in the Strategic Technologies Program. With over 30 years of U.S. Department of Defense experience, she specializes in adapting national security frameworks to technological disruptions. Her academic credentials include: Ph.D. in Political Science from the Massachusetts Institute of Technology MPA from Princeton University B.A. with Honors from Cornell University Dr. Kuntz's research bridges defense strategy and emerging technologies, focusing on AI governance in military contexts and biotechnological threats. Her work analyzes autonomous weapons ethics, genome editing risks, and WMD defense systems through interdisciplinary lenses spanning computer science, political theory, and public health policy. Recent publications examine AI integration in warfare and genome manipulation governance, revealing consistent themes of proactive policy design for technological existential risks. These studies highlight her strategic approach to anticipating security vulnerabilities before crises emerge. Her accolades include: Secretary of Defense Medal for Meritorious Civilian Service (awarded twice) Dr. Kuntz's government leadership encompassed directing Project Bioshield and the Domestic Nuclear Detection Office, demonstrating extensive grant management and interagency coordination expertise. Her academic mentorship leverages decades of high-stakes policy implementation experience. At CSIS, she contributes to strategic technology assessments while maintaining active academic roles. Her career trajectory—from Cold War defense planning to AI policy—exemplifies continuous adaptation to evolving security paradigms through institutional collaboration.

• Artificial Intelligence Policy
• Biodefense
• National Security Policy
• +۳ مورد دیگر

Theodore C Bania, MD, is an Assistant Professor of Emergency Medicine at the Icahn School of Medicine at Mount Sinai, holding multiple leadership roles including Associate Dean for Human Subjects Research Protection, IRB Chair, and Director of Medical Toxicology at Mount Sinai West and Morningside. He specializes in emergency medicine and medical toxicology, with a focus on lipid resuscitation therapy for drug toxicity and HIV education via mobile devices. Education: MD from SUNY Downstate Health Sciences University, fellowship in Medical Toxicology at NYU, and a Master of Science in Clinical Research from Albert Einstein College of Medicine. Research interests include cardiovascular drug toxicity, chemical warfare agents, substance abuse education, and research ethics. His work has led to advancements in lipid therapy models and HIV/HCV education strategies. He has received NIH/NIDA grants and holds the 2010 Super Doctor award. He oversees over 25 years of research at Mount Sinai’s emergency departments and chairs institutional review boards. His publications span toxicology, bioethics, and clinical practices.

• Medical Toxicology
• HIV/AIDS Research
• Substance Use Disorders
• +۴ مورد دیگر

Crystal R. Watson is an Associate Professor in the Department of Environmental Health and Engineering at Johns Hopkins University, with a joint role as Senior Associate at the Johns Hopkins Center for Health Security. She specializes in public health preparedness, risk assessment during emergencies, and biodefense policy. She holds a DrPH and MPH from the Johns Hopkins Bloomberg School of Public Health and a BA from the University of Colorado. Her research focuses on federal funding and management of biodefense programs, crisis decision-making, and global health security. Notable projects include assessments of Taiwan’s IHR compliance and analysis of Hurricane Katrina’s medical response. She serves as Associate Editor of Health Security and has authored over 30 peer-reviewed articles. Key contributions include publications on biological threat characterization, pandemic event management, and Ebola risk perception. She advises on policies to address catastrophic biological risks and has led projects funded by federal agencies.

• Public Health Preparedness
• Biodefense
• Risk Assessment
• +۳ مورد دیگر

Jennifer Golden is an Associate Professor in the Department of Pharmaceutical Sciences at the School of Pharmacy , University of Wisconsin-Madison . Her research focuses on synthetic medicinal chemistry to develop novel antiviral and anti-parasitic agents for diseases like alphavirus infections and kinetoplastid parasites. The Golden Lab emphasizes chemical methodology development and structure-activity relationship analysis through collaborations assessing compound efficacy in cell and animal models . Research Projects Quinazolinone Rearrangement: Developing synthetic transformations for amidine formation and ring-fused scaffolds. Anti-Alphaviral Agents: Creating FDA-approved therapeutic candidates for mosquito-borne RNA viruses. Broad-Spectrum Antiparasitics: Optimizing compounds for malaria, African sleeping sickness, and leishmaniasis. Publications highlight her work on ML336 (anti-VEEV), quinazolinone derivatives , and collaborations with experts in high-throughput screening and structural biology . Her lab trains students in hit-to-lead optimization , regioselective synthesis , and medicinal chemistry tactics . Education: B.S. (1996) – Eastern Illinois University Ph.D. (2002) – University of Kansas Postdoctoral Research (2004) – Stanford University

• Synthetic Medicinal Chemistry
• Antiviral Drug Development
• Antiparasitic Drug Discovery
• +۳ مورد دیگر

Yuri Y. Gleba is a renowned academic scientist affiliated with the Institute of Cell Biology and Genetic Engineering at the Ukrainian Academy of Sciences in Kiev, Ukraine. As Founder and Director (1989–2010) and current Honorary Director, he has shaped plant biotechnology research through pioneering work in transient expression systems and molecular farming. Key Roles: Founder and Director of Institute of Cell Biology and Genetic Engineering (1989–2010), Honorary Director (2010–present) Research Interests Plant genetics , plant physiology , and biotechnology underpin his work in genetic engineering , viral vector systems , and transgenic plant applications . His innovations include the Magnifection platform for rapid plant-based vaccine production and methods for RNA silencing enhancement in molecular farming. Scientific Recognition includes membership in six international academies (World Academy of Arts and Science, Academia Europaea, Leopoldina, Ukrainian Academy of Sciences, Lithuanian Academy of Science, Bavarian Academy of Sciences) and prestigious awards like the Koerber Prize , A. von Humboldt Prize , and state prizes from the USSR and Ukraine. His work has appeared in top journals including Proceedings of the National Academy of Sciences USA and FEBS Letters . Publications : Gleba's 15 most recent articles (2004–2010) focus on plant biotechnology applications, viral vector engineering, and molecular farming. Key trends include plant-based pharmaceutical production , transient expression systems , and transgene containment strategies . Laboratory and Collaborations : Founded and led the Institute of Cell Biology and Genetic Engineering, fostering international collaborations in plant biotechnology and genetic engineering research.

• Plant genetics
• Plant physiology
• Plant cell biology
• +۳ مورد دیگر

Lawrence M. Wein is the Jeffrey S. Skoll Professor of Management Science at Stanford University's Graduate School of Business, where he also serves as Senior Associate Dean of Academic Affairs. He holds a PhD in Operations Research from Stanford (1988) and has taught operations management at MIT (1988–2002) and Stanford since 2003. His research spans operations management, public health, and homeland security, with notable contributions to HIV therapy optimization, bioterror response logistics, and forensic science innovations. His academic roles include Senior Fellow at Stanford’s Center for International Security and Cooperation, and editorial leadership as Editor-in-Chief of Operations Research (2000–2005). Notable awards include the Kimball Medal, Lanchester Prize, and membership in the National Academy of Engineering. Research interests emphasize applying operations research to real-world challenges, such as optimizing radiation detection systems, analyzing sexual assault kit backlogs, and improving ballistic imaging techniques. His work bridges theoretical models with practical policy, impacting areas like healthcare, counterterrorism, and criminal justice. Key contributions include developing the workload regulating release policy in semiconductor manufacturing, influencing U.S. smallpox vaccination strategy, and advancing mathematical models for cancer treatment and pandemic influenza control. His recent focus includes forensic genetic genealogy and crime-solving technologies. Grants and collaborations span industries, governments, and academic institutions, reflecting interdisciplinary impact. His teaching includes courses on operations management, stochastic networks, and homeland security applications.

• Operations Management
• Public Health
• Homeland Security
• +۵ مورد دیگر

Professor Joe Burton is a leading academic in International Security at Lancaster University's Department of Politics, Philosophy and Religion (PPR). He joined Lancaster in July 2023 as part of the Security and Protection Science initiative, following roles at the University of Nottingham, University of St Andrews, and as a Marie Curie Fellow at Université libre de Bruxelles. His expertise spans cyber conflict, emerging technologies, and interdisciplinary security studies. Education: Doctorate in International Relations, University of Otago Master of International Studies, University of Otago Bachelor of International Relations, University of Wales, Aberystwyth Research interests include cyber security, terrorism, organized crime, maritime security, norm diffusion, and non-proliferation. He has advised governments in New Zealand and the UK, participated in ASEAN policy processes, and conducted research funded by NATO, the EU, and U.S./Taiwan governments. Awards include the US Department of State SUSI Fellowship and Taiwan Fellowship. His grants include projects on cyber deterrence, NATO-EU cooperation, and cyber-biodefense strategies. He leads the CYBER MALCULT project (2024–2027) on countering malicious online security cultures. He collaborates with Security Lancaster research groups focusing on behavioral science, policing, law/ethics, secure machine learning, societal threats, and sociology. His advisory work spans cyber warfare, AI ethics, and transatlantic security policy.

• Cyber Conflict
• Emerging Technologies
• Cyber Security
• +۸ مورد دیگر

Richard Silberglitt is a Senior Physical Scientist at RAND and Professor of Policy Analysis at the RAND School of Public Policy, where he conducts interdisciplinary research at the nexus of science, technology, and public policy. With over 50 years of experience across academia, government, and industry, he is a leading expert in technology foresight, energy systems, and R&D portfolio management. His research focuses on emerging technologies , science and innovation policy , energy security , and nanotechnology . He has developed influential methodologies such as an energy scenario analysis framework and the PortMan portfolio management system, both widely applied in U.S. and international contexts. His work supports strategic planning in defense, public safety, and economic development. His recent publications reflect a strong trend toward technology foresight , critical materials supply chains , quantum technology assessment , and public sector innovation . These works often employ scenario planning, Delphi methods, and data-driven analytics to inform high-stakes policy decisions. Member, American Physical Society Member, Materials Research Society Member, American Ceramic Society As a subject matter expert, Silberglitt has advised the United Nations, U.S. Department of Defense, National Security Agency, and multiple federal agencies. He has chaired the International Advisory Board of the APEC Center for Technology Foresight and delivered testimony to U.S. Congressional committees on critical materials and technology policy. His research has been supported by grants and contracts from the U.S. Army, Navy, CDC, and National Institute of Justice. He has led major initiatives on law enforcement technology, transportation safety ( The Road to Zero ), and international technology foresight. His work often involves collaborative teams and cross-sector partnerships to address complex technological and policy challenges.

• Emerging Technologies
• Science, Technology, and Innovation Policy
• Energy Security
• +۱۷ مورد دیگر

David Ridley is a Professor at Duke University's Fuqua School of Business with additional appointments in the Department of Economics and Sanford School of Public Policy. He serves as Faculty Director of the Center for Health Sector Management (HSM) and is an Executive Core Faculty Member at the Duke-Margolis Institute for Health Policy. His work bridges business, economics, and public policy with a focus on healthcare innovation and policy. Ridley earned his Ph.D. from Duke University in 2001. His academic journey has been focused on applying economic principles to solve complex healthcare challenges, particularly in pharmaceutical markets and global health. Ridley's research centers on health economics , with special emphasis on incentives for innovation and pharmaceutical pricing . He is best known for developing the priority review voucher system, which creates market-based incentives for developing treatments for neglected diseases. His work examines how regulatory frameworks, pricing mechanisms, and market structures influence healthcare innovation and access. Through his research, Ridley has demonstrated how economic tools can be applied to improve health outcomes globally, particularly for underserved populations. Analysis of Ridley's recent publications reveals a consistent focus on pharmaceutical policy, with particular attention to incentive mechanisms like priority review vouchers. His work spans both theoretical economic analysis and practical policy applications, often examining how regulatory decisions impact drug development, pricing, and access. A significant portion of his research addresses neglected tropical diseases and the economic barriers to developing treatments for these conditions. Ridley has led significant research initiatives including the development of the FDA priority review voucher program (2007) and the EPA vector expedited review voucher program (2022). These policy innovations have created market-based incentives for developing treatments for neglected diseases, with the FDA having awarded more than 80 vouchers valued at approximately $100 million each. As Faculty Director of the Center for Health Sector Management, Ridley oversees a program that comprises about 20 percent of Duke MBA graduates each year. His grant portfolio includes significant funding for research on neglected tropical diseases, antimicrobial resistance, and biodefense. Current projects include "The Commercial Value of Pull Mechanisms for Drug Development in Neglected Tropical Diseases" (2024-2025) and "The Next Phase of Antimicrobial Resistance Payment Policy" (2022-2023). Ridley leads and participates in several research teams focused on healthcare innovation and policy. His work with the Duke-Margolis Institute for Health Policy connects academic research with practical policy applications. Through the Center for Health Sector Management, he fosters collaboration between business students and healthcare professionals to address pressing challenges in the health sector.

• Health Economics
• Pharmaceutical Policy
• Innovation Incentives
• +۴ مورد دیگر

Sonia Ben Ouagrham-Gormley is an Associate Professor at the Schar School of Policy and Government, George Mason University. She is affiliated with the Biodefense Program, the Center for Global Studies, and the Department of History and Art History’s Master of Arts in Interdisciplinary Studies (MAIS) program. Her work bridges policy, security, and science, with a regional focus on the former Soviet Union. Her research centers on the proliferation of weapons of mass destruction, including nuclear, chemical, and biological weapons. She investigates how tacit knowledge affects weapons development, the effectiveness of export controls, and the challenges of dissuading bioweapons programs. Her work also covers WMD-related trafficking, sanctions, and the redirection of former weapons scientists. She employs qualitative methods and interdisciplinary frameworks from science and technology studies. She has secured research funding from the U.S. Departments of Defense, State, and Energy, as well as from the Nuclear Threat Initiative and the Carnegie Corporation of New York. Her work contributes to programs such as the Department of Defense’s Cooperative Threat Reduction Program, aimed at reducing global WMD risks. Ben Ouagrham-Gormley has held significant research roles, including Senior Research Associate at the James Martin Center for Nonproliferation Studies (CNS), where she directed research at the CNS Almaty office in Kazakhstan. She was also the founding Editor-in-Chief of the International Export Control Observer and served as an Adjunct Professor at Johns Hopkins University School of Advanced International Studies. Her educational background includes a PhD in Development Economics from EHESS in Paris, a graduate degree in Strategy and Defense Policy from the Institute of Higher International Studies in Paris, a Master’s in Applied Foreign Languages (economics, law, Russian, and English) from the University of Paris X-Nanterre, and dual undergraduate degrees in Applied Foreign Languages and English Literature from the same institution. She is fluent in French, English, Russian, and spoken Arabic, with beginner-level Kazakh. Her multilingual abilities support her field research and international collaborations, particularly in post-Soviet states.

• Weapons of Mass Destruction (WMD) Proliferation
• Nonproliferation and Arms Control
• Biodefense
• +۱۶ مورد دیگر

Hulin Wu, PhD is a Professor at the University of Texas Health Science Center at Houston (UTHealth) School of Public Health and Chair of the Department of Biostatistics & Data Science. He holds the Betty Wheless Trotter Professorship and Dr. D.R. Seth Family Professorship in Biostatistics. Trained with an MS in Engineering and a PhD in Statistics, Wu specializes in statistical methods for longitudinal data analysis, differential equation models, and their biomedical applications in clinical trials, bioinformatics, and immunology. His work focuses on infectious diseases like HIV, influenza, and bacterial infections, alongside big data analysis and community-based health studies. Research Interests : Biostatistical modeling, dynamic systems in health data, clinical trial design, EHR integration, and -omics applications in infectious disease modeling. Leadership : Joined UTHealth in 2015 as Dr. D.R. Seth Family Professor and Associate Chair of Biostatistics, later becoming Chair in 2017. Previously held roles at the University of Rochester Medical Center. Funding : Continuously funded by NIH since 1998 as PI/Co-PI for R01, T32 training grants, and center grants, including directing the NIH-funded Center for Biodefense Immune Modeling (2005-2015). Publications : Authored 2 books and over 130 peer-reviewed papers in top journals like JASA , Biometrika , and Journal of Immunology .

• Biostatistics
• Big Data/Data Science
• Clinical Trials
• +۷ مورد دیگر

Paul Keim is a Distinguished Professor at Northern Arizona University and holds the Cowden Endowed Chair in Microbiology. He serves as a Regents Professor of Biology and leads the Pathogen Genomics Program, a joint initiative between TGen and Northern Arizona University. His work focuses on bacterial pathogen genomics, biodefense, and molecular epidemiology. Institution: Northern Arizona University & TGen Division: Immunology and Microbial Genomics Division Email: pkeim@tgen.org Dr. Keim specializes in genomic forensic analysis of biothreat agents like Bacillus anthracis (anthrax), Yersinia pestis (plague), and Francisella tularensis (tularemia). His research includes understanding pathogen evolution, ecology, and epidemiology to develop advanced diagnostics and therapeutics. He has collaborated with federal agencies on bioterrorism response, notably providing critical forensic analysis during the 2001 anthrax attacks. Key publication trends include genomic surveillance of bacterial pathogens, evolutionary dynamics , and molecular identification tools . His studies often employ whole-genome sequencing , SNP analysis , and MLVA techniques. Scientific Awards Cowden Endowed Chair in Microbiology, Northern Arizona University Dr. Keim's work has shaped modern bioforensic methodologies , particularly for anthrax and plague. His lab's 1993 analysis of the Tokyo anthrax attack linked it to Aum Shinrikyo, establishing genomic tools as critical for biocrime investigations.

• Pathogen Genomics
• Molecular Epidemiology
• Bacterial Pathogens
• +۶ مورد دیگر

John R. Morris is a Professor of Chemistry and Associate Dean for Research at the College of Science, Virginia Tech. He holds the Dr. A.C. Lilly Jr. Faculty Fellowship in Nanoscience. His research focuses on interfacial chemistry, with emphasis on gas-surface reactions, catalysis, and chemical sensing. Key projects include chemical warfare agent detection, environmental pollutant interactions, and energy materials. Education: B.S., Aquinas College, 1991 Ph.D., University of Notre Dame, 1996 Postdoctoral Associate, University of Wisconsin-Madison, 1996–1999 Research Interests: Dr. Morris explores molecular mechanisms in gas-surface interactions using advanced techniques like molecular beam scattering and ultrahigh vacuum spectroscopy. His work addresses environmental chemistry (e.g., atmospheric pollutants), energy storage (e.g., MOFs for diborane), and defense applications (e.g., nerve agent decomposition). Recent studies include photocatalytic oxidation mechanisms on Au/TiO₂ and the development of novel sensors for volatile organic compounds. Awards: National Science Foundation CAREER Award (2001) Army Research Office Young Investigator Award (2001) Schug Research Award (2012) Advising & Grants: Morris has mentored over 10 students and led projects funded by NSF, DoD, and industry. His lab (005 Hahn Hall South) focuses on interdisciplinary collaborations in materials science and environmental chemistry. Labs/Teams: The Morris Group operates a state-of-the-art facility for studying gas-surface reactions, including custom-built chambers for CRDS and molecular beam experiments.

• Analytical Chemistry
• Energy Materials
• Environmental Chemistry
• +۶ مورد دیگر

Eileen M. Barry serves as Professor in the Department of Medicine at the University of Maryland School of Medicine, with secondary appointments in Medical and Research Technology and Microbiology and Immunology. She directs education for the Center of Vaccine Development & Global Health, leading research on vaccines against enteric pathogens and biodefense threats. Her academic background includes: B.A. in Biology from University of Delaware (1985) Ph.D. in Microbiology and Immunology from Virginia Commonwealth University Medical College of Virginia (1991) Postdoctoral Fellowship at University of Maryland School of Medicine Center for Vaccine Development (1992-1994) Postdoctoral Fellowship at University of Maryland School of Medicine Center for Vaccine Development (1994-1996) Dr. Barry's research focuses on oral live attenuated vaccines targeting Shigella , enterotoxigenic E. coli (ETEC), and Francisella tularensis . Her work spans pathogen engineering, host-pathogen interactions, and clinical translation, with emphasis on pediatric and military applications. Key methodologies include human enteroid models, BSL3/ABSL3 pathogenesis studies, and immunogenicity assessment. Recent publications reveal a strategic shift toward multivalent platforms and advanced organoid systems for predicting human immune responses. Her scientific recognition includes: University System of Maryland PROMISE Alliance Outstanding Faculty Mentor (2015) Faculty Teacher of the Year Award (2011) Teaching Commendation in Host Defenses (2009/2012) As a dedicated mentor, Dr. Barry has served on Graduate Student Admissions Committees since 2007 and received special recognition for advancing underrepresented STEM students. Her substantial NIH funding portfolio includes: P01AI125181: Pathogenesis of E. Coli and Shigella in Human Enteroid Models (2016-2021) R01AI125841: Serological Assays for Shigella Vaccine Efficacy (2016-2021) R01AI123129: Tularemia Vaccine Protection Correlates (2016-2021) Her laboratory operates BSL2/3 and ABSL2/3 facilities, integrating genetic engineering, organoid models, and genomics to dissect enteric pathogenesis and accelerate vaccine development for global health impact.

• Vaccine Development
• Enteric Pathogens
• Shigella
• +۵ مورد دیگر

Dr. Steven Aronin is an Associate Clinical Professor of Medicine at Yale School of Medicine and serves as Chief of Infectious Disease at Waterbury Hospital. He holds multiple leadership roles including Medical Director of the Waterbury Hospital Infectious Disease and Travel Clinic, Program Director for Ryan White HIV Programs, and Hospital Epidemiologist. His academic work focuses on infectious diseases, particularly meningitis, endocarditis, HIV/AIDS, and antibiotic efficacy. Dr. Aronin completed his MD at Ross University School of Medicine and residency at Yale Primary Care Internal Medicine Program. He has been a Core Faculty member at Waterbury Hospital since 2009 and oversees the Yale-Waterbury Internal Medicine Residency Program's Infectious Disease training. He is also President of the Connecticut Infectious Disease Society. His research emphasizes translational antibiotic studies, particularly sulopenem's efficacy against resistant pathogens like E. coli and K. pneumoniae. Recent work includes phase 3 trials comparing sulopenem to ertapenem for intra-abdominal infections, and evaluating its use in UTIs and anthrax models. Key findings include sulopenem's superior efficacy in UTIs and its potential as a biodefense agent against inhalational anthrax. Dr. Aronin actively contributes to clinical guidelines through studies on HIV screening integration and bacteriuria's clinical impact. His work bridges academic research with direct patient care, emphasizing antibiotic stewardship and improving infectious disease treatment outcomes.

• Infectious Diseases
• HIV/AIDS Research
• Antimicrobial Resistance
• +۵ مورد دیگر